  Biopolymer self-assembly pathways are central to biological activity, but are
complicated by the ability of the monomeric subunits of biopolymers to adopt
different conformational states. As a result, biopolymer nucleation often
involves a two-step mechanism where the monomers first condense to form a
metastable intermediate, and this then converts to a stable polymer by
conformational rearrangement of its constituent monomers. While existing
mathematical models neglect the dynamics by which intermediates convert to
stable polymers, experiments and simulations show that these dynamics
frequently occur on comparable timescales to condensation of intermediates and
growth of mature polymers, and thus cannot be ignored. Moreover, nucleation
intermediates are responsible for cell toxicity in pathologies such as
Alzheimer's, Parkinson's, and prion diseases. Due to the relationship between
conformation and biological function, the slow conversion dynamics of these
species will strongly affect their toxicity. In this study, we present a
modified Oosawa model which explicitly accounts for simultaneous assembly and
conversion. To describe the conversion dynamics, we propose an experimentally
motivated initiation-propagation (IP) mechanism in which the stable phase
arises locally within the intermediate, and then spreads through additional
conversion events induced by nearest-neighbor interactions, analogous to
one-dimensional Glauber dynamics. Our mathematical analysis shows that the
competing timescales of assembly and conversion result in a nonequilibrium
critical point, separating a regime where intermediates are kinetically
unstable from one where conformationally mixed intermediates can accumulate.
Our work provides the first general model of two-step biopolymer nucleation,
which can be used to quantitatively predict the concentration and composition
of biologically crucial intermediates.
